Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies

Simple item page
dc.contributor.authorSingla, Heena
dc.contributor.authorLudhiadch, Abhilash
dc.contributor.authorKaur, Raman Preet
dc.contributor.authorChander, Harish
dc.contributor.authorKumar, Vinod
dc.contributor.authorMunshi, Anjana
dc.date.accessioned2018-07-14T01:19:06Z
dc.date.accessioned2024-08-14T07:41:21Z
dc.date.available2018-07-14T01:19:06Z
dc.date.available2024-08-14T07:41:21Z
dc.date.issued2017
dc.description.abstractHER2 amplification/overexpression accounts for aggressive clinical features of HER2 positive breast cancer. Epigenetic changes including DNA methylation, histone modifications and ncRNAs/miRNAs are associated with regulation of DNA chromatin and specifically, gene transcription. Hence, these produce eminent effects upon proto-oncogenes, tumor-suppressors and key cancer-regulatory signaling pathways. Understanding of epigenomic regulation of HER2 overexpression and signaling may help uncover the unmatchable physiology of HER2 gene/protein. Moreover, this may also aid in resolving the major issue of resistance-development towards HER2 targeted agents (trastuzumab and lapatinib), since epigenetic alterations are important therapeutic markers and modulate the response towards HER2 targeted therapy. Therefore, in this review the information regarding various epigenetic markers implicated in HER2 positive breast cancer susceptibility and therapeutic-strategies has been compiled. ? 2017 Elsevier Masson SASen_US
dc.identifier.citationSingla, H., Ludhiadch, A., Kaur, R. P., Chander, H., Kumar, V., & Munshi, A. (2017). Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies. European Journal of Medicinal Chemistry, 142, 316-327. doi: 10.1016/j.ejmech.2017.07.075en_US
dc.identifier.doi10.1016/j.ejmech.2017.07.075
dc.identifier.issn2235234
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/1443
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0223523417305974?via%3Dihub
dc.language.isoen_USen_US
dc.publisherElsevier Masson SASen_US
dc.subjectDnaen_US
dc.subjectEstrogen Receptor Alphaen_US
dc.subjectHistoneen_US
dc.subjectLapatiniben_US
dc.subjectMethyltransferaseen_US
dc.subjectTrastuzumaben_US
dc.subjectTumor Promoteren_US
dc.subjectUntranslated Rnaen_US
dc.subjectEpidermal Growth Factor Receptor 2en_US
dc.subjectErbb2 Protein, Humanen_US
dc.subjectImmunological Antineoplastic Agenten_US
dc.subjectLapatiniben_US
dc.subjectProtein Kinase Inhibitoren_US
dc.subjectQuinazoline Derivativeen_US
dc.subjectTrastuzumaben_US
dc.subjectCancer Prognosisen_US
dc.subjectCancer Susceptibilityen_US
dc.subjectDna Methylationen_US
dc.subjectEpigeneticsen_US
dc.subjectHistone Modificationen_US
dc.subjectHistopathologyen_US
dc.subjectHumanen_US
dc.subjectHuman Epidermal Growth Factor Receptor 2 Positive Breast Canceren_US
dc.subjectModulationen_US
dc.subjectPrognostic Assessmenten_US
dc.titleRecent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategiesen_US
dc.title.journalEuropean Journal of Medicinal Chemistry
dc.typeReviewen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
3400.pdf
Size:
992 KB
Format:
Adobe Portable Document Format
Download

Collections

Human Genetics And Molecular Medicine - Research Publications